Literature DB >> 24857830

Intestinal dysbiosis: novel mechanisms by which gut microbes trigger and prevent disease.

Mark A Underwood1.   

Abstract

New research has identified specific intestinal colonizing microbes that can have significant influence on health and disease. Evidence is reviewed supporting an association between Fusobacterium nucleatum and colon cancer and for a protective role of Faecalibacterium prausnitzii in inflammatory bowel disease, of Escherichia coli Nissle 1917 in acute intestinal inflammation, of Bifidobacterium infantis in neonatal necrotizing enterocolitis, and of Akkermansia muciniphila in obesity and diabetes. These novel bacteria are clinically relevant and present opportunities for more focused diagnosis of colon cancer and prevention of common diseases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute intestinal inflammation; Akkermansia muciniphila; Bifidobacterium infantis; Colon cancer; Escherichia coli Nissle 1917; Faecalibacterium prausnitzii; Fusobacterium nucleatum; Inflammatory bowel disease; Necrotizing enterocolitis; Obesity

Mesh:

Year:  2014        PMID: 24857830     DOI: 10.1016/j.ypmed.2014.05.010

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  16 in total

Review 1.  Prevention of Necrotizing Enterocolitis Through Manipulation of the Intestinal Microbiota of the Premature Infant.

Authors:  Kannikar Vongbhavit; Mark A Underwood
Journal:  Clin Ther       Date:  2016-02-09       Impact factor: 3.393

Review 2.  Microbiota modulation of myeloid cells in cancer therapy.

Authors:  Romina S Goldszmid; Amiran Dzutsev; Sophie Viaud; Laurence Zitvogel; Nicholas P Restifo; Giorgio Trinchieri
Journal:  Cancer Immunol Res       Date:  2015-02       Impact factor: 11.151

3.  Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study.

Authors:  Federica Del Chierico; Melania Manco; Simone Gardini; Valerio Guarrasi; Alessandra Russo; Marzia Bianchi; Valentina Tortosa; Andrea Quagliariello; Blegina Shashaj; Danilo Fintini; Lorenza Putignani
Journal:  Acta Diabetol       Date:  2021-03-22       Impact factor: 4.280

Review 4.  The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.

Authors:  Taha Qazi; Thelina Amaratunga; Edward L Barnes; Monika Fischer; Zain Kassam; Jessica R Allegretti
Journal:  Gut Microbes       Date:  2017-09-12

5.  Cancer Immunity: Lessons From Infectious Diseases.

Authors:  Giorgio Trinchieri
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

Review 6.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

Review 7.  Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma.

Authors:  Antonio Galvao Neto; April Whitaker; Zhiheng Pei
Journal:  Semin Oncol       Date:  2015-09-07       Impact factor: 4.929

8.  Probiotic Administration in Infants With Gastroschisis: A Pilot Randomized Placebo-Controlled Trial.

Authors:  Weston T Powell; Robyn A Borghese; Karen M Kalanetra; Majid Mirmiran; David A Mills; Mark A Underwood
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-06       Impact factor: 2.839

9.  Faecal microbiota characterisation of horses using 16 rdna barcoded pyrosequencing, and carriage rate of clostridium difficile at hospital admission.

Authors:  Cristina Rodriguez; Bernard Taminiau; Bastien Brévers; Véronique Avesani; Johan Van Broeck; Aurélia Leroux; Marjorie Gallot; Antoine Bruwier; Hélene Amory; Michel Delmée; Georges Daube
Journal:  BMC Microbiol       Date:  2015-09-16       Impact factor: 3.605

10.  Tea polyphenols inhibit the activation of NF-κB and the secretion of cytokines and matrix metalloproteinases by macrophages stimulated with Fusobacterium nucleatum.

Authors:  Amel Ben Lagha; Daniel Grenier
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.